EYP-1901 for Retinal Exudative Diseases

Updates from the clinical trial program in Wet AMD and DME

By
Ashkan M. Abbey
May 29, 2026
6 min

The Ophthalmologist

Overview

EYP-1901, a sustained-release intravitreal insert, shows results in phase 2 trials for wet AMD and DME, demonstrating noninferiority to aflibercept and extended treatment-free intervals. Ongoing phase 3 trials are evaluating its efficacy and safety.

Background

Retinal exudative diseases, such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME), pose significant challenges in clinical management, with many patients experiencing vision loss despite current anti-VEGF therapies. The need for more durable treatment options is critical due to the high burden of frequent injections and treatment discontinuation rates. EYP-1901 represents a novel approach, combining anti-VEGF and anti-inflammatory mechanisms.

Data Highlights

Trial	Primary Endpoint	Results
DAVIO 2	Noninferiority to aflibercept	Stable or improved vision in >85% of patients
VERONA	Extended time to first supplemental treatment	70% supplement-free at Week 24 with EYP-1901 2.7 mg

Key Findings

EYP-1901 demonstrated noninferiority to aflibercept in the DAVIO 2 trial based on BCVA change.
Over 85% of patients treated with EYP-1901 maintained stable or improved vision six months post-treatment.
In the VERONA trial, both EYP-1901 doses achieved longer time to first supplemental treatment compared to aflibercept.
Mean BCVA improvements were +6.9, +7.1, and +7.3 letters for EYP-1901 1.3 mg, 2.7 mg, and aflibercept 2 mg, respectively.

Clinical Implications

The findings from the DAVIO 2 and VERONA trials suggest that EYP-1901 may reduce the treatment burden associated with current therapies while maintaining vision outcomes. Ongoing phase 3 trials will provide further insights into its long-term efficacy and safety in clinical practice.

Conclusion

EYP-1901 shows promise as a durable treatment option for retinal exudative diseases, with ongoing trials expected to clarify its role in clinical management.